Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Vascular endothelial growth factor (VEGF) inhibitors—approved agents Eylea (Regeneron) and Lucentis (Roche/Genentech), and off-label Avastin (Roche/Genentech)—are the treatment mainstays for diabetic macular edema (DME). Allergan’s Ozurdex and Alimera Sciences’ Iluvien, two long-acting corticosteroid implants, are also used to treat DME. The market heated up in April 2017 when the label of Lucentis 0.3 mg was expanded to treat patients with diabetic retinopathy (DR) without DME. Factoring in the anticipated approval of Eylea for nonproliferative DR patients without DME in the United States, as well as the expected availability of biosimilars of Lucentis 0.5 mg and Eylea and emerging therapies for DME, this report delivers actionable insights to help companies best position their DME/DR products to succeed in the U.S. access and reimbursement environment.
Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.
Markets covered: United States
Key companies: Roche/Genentech, Regeneron, Alimera Sciences, Allergan, Allegro Ophthalmics
Key drugs: Avastin, Eylea, Lucentis, Iluvien, Ozurdex, RG-7716, Luminate, abicipar pegol